Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116785285> ?p ?o ?g. }
- W2116785285 endingPage "109" @default.
- W2116785285 startingPage "90" @default.
- W2116785285 abstract "Over the last 2 decades, four major therapeutic approaches have drastically changed the prognosis in chronic myelogenous leukemia (CML): 1) allogeneic stem cell transplant (SCT); 2) interferon alpha (IFN-alpha) based regimens; 3) donor lymphocyte infusions (DLI); and 4) and the revolutionary BCR-ABL tyrosine kinase inhibitors such as STI571 (signal transduction inhibitor 571). Each modality has exploited and targeted different aspects of CML biology, and is associated with different risk-benefit ratios. In Section I of this review, Dr. Melo reviews the molecular pathophysiology of CML and potential new targets for therapy including anti-sense strategies to disrupt the BCR-ABL gene and inhibition of the BCR-ABL tyrosine kinase activity. In Section II, Dr. Tura, addresses important questions in the use of IFN-alpha for the treatment of CML, including the mechanism of action and the development of resistance, the optimal dose and duration of therapy and the prediction of response based on clinical features. An approach to the choice of therapy based on the predicted mortality is presented. In Section III Dr. Giralt presents an update on the results of unrelated donor transplantion, donor lymphocyte infusions (DLI) and non-ablative stem cell transplantation (NST) in CML. The roles of CD8-depletion, dose escalation and the transduction of suicide genes in treatment with DLI are addressed. Early results of NST in CML show that it is feasible and can result in long-term disease control. In Section IV Drs. Kantarjian and Talpaz review the results of IFN-alpha plus low-dose cytosine arabinoside and other promising modalities for CML including homoharringtonine, decitabine, and polyethylene glycol-interferon. In Section V they present an update on the recent experience with STI571. Objective but transient responses have been seen in 40% to 50% of patients in CML blastic phase. In accelerated phase, the response rate with STI571 exceeds 70%, and these responses are durable. In chronic phase CML, STI571 at 300 mg daily in patients who failed IFN-alpha produces a complete hematologic response (CHR) in over 90% of patients. Early results suggest cytogenetic response rates of approximately 50%, which may be major in approximately 30%. The maturing results with STI571 may soon change current recommendations regarding the relative roles of established modalities such as allogeneic SCT and IFN-alpha. Important questions include 1) whether STI571 therapy alone may be sufficient to induce long-term survival and event-free survival in CML, or whether it needs to be combined simultaneously or sequentially with IFN-alpha and cytosine arabinoside; and 2) what should the indications for frontline allogeneic SCT be in relation to STI571 therapy." @default.
- W2116785285 created "2016-06-24" @default.
- W2116785285 creator A5011529063 @default.
- W2116785285 creator A5033359713 @default.
- W2116785285 creator A5042107262 @default.
- W2116785285 creator A5070096873 @default.
- W2116785285 creator A5084379902 @default.
- W2116785285 date "2000-01-01" @default.
- W2116785285 modified "2023-10-16" @default.
- W2116785285 title "Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies" @default.
- W2116785285 cites W107716097 @default.
- W2116785285 cites W111932728 @default.
- W2116785285 cites W120419820 @default.
- W2116785285 cites W120676909 @default.
- W2116785285 cites W125081235 @default.
- W2116785285 cites W126560450 @default.
- W2116785285 cites W1486674271 @default.
- W2116785285 cites W1490860457 @default.
- W2116785285 cites W1498708301 @default.
- W2116785285 cites W1501664116 @default.
- W2116785285 cites W1520440593 @default.
- W2116785285 cites W1534632891 @default.
- W2116785285 cites W1560035984 @default.
- W2116785285 cites W1571009995 @default.
- W2116785285 cites W1582758242 @default.
- W2116785285 cites W1589162162 @default.
- W2116785285 cites W1592881318 @default.
- W2116785285 cites W1599349966 @default.
- W2116785285 cites W1614759083 @default.
- W2116785285 cites W1707184873 @default.
- W2116785285 cites W1719330231 @default.
- W2116785285 cites W175951554 @default.
- W2116785285 cites W1799579309 @default.
- W2116785285 cites W1873141201 @default.
- W2116785285 cites W188630774 @default.
- W2116785285 cites W1901923962 @default.
- W2116785285 cites W1928548710 @default.
- W2116785285 cites W1964445294 @default.
- W2116785285 cites W1970161464 @default.
- W2116785285 cites W1985163185 @default.
- W2116785285 cites W1992798892 @default.
- W2116785285 cites W2006518962 @default.
- W2116785285 cites W2010012100 @default.
- W2116785285 cites W201066153 @default.
- W2116785285 cites W2016086822 @default.
- W2116785285 cites W2020707154 @default.
- W2116785285 cites W2025383600 @default.
- W2116785285 cites W2025574559 @default.
- W2116785285 cites W2038990138 @default.
- W2116785285 cites W2040261377 @default.
- W2116785285 cites W204705285 @default.
- W2116785285 cites W2058190985 @default.
- W2116785285 cites W2058839845 @default.
- W2116785285 cites W2067635683 @default.
- W2116785285 cites W2067652212 @default.
- W2116785285 cites W2071878999 @default.
- W2116785285 cites W2076372887 @default.
- W2116785285 cites W2085358525 @default.
- W2116785285 cites W2088033042 @default.
- W2116785285 cites W2089697181 @default.
- W2116785285 cites W2097384422 @default.
- W2116785285 cites W2101056299 @default.
- W2116785285 cites W2117806883 @default.
- W2116785285 cites W2120756704 @default.
- W2116785285 cites W2122797075 @default.
- W2116785285 cites W2138172881 @default.
- W2116785285 cites W2140899794 @default.
- W2116785285 cites W2142618806 @default.
- W2116785285 cites W2153787194 @default.
- W2116785285 cites W2207680991 @default.
- W2116785285 cites W2229948807 @default.
- W2116785285 cites W2258838187 @default.
- W2116785285 cites W2262832347 @default.
- W2116785285 cites W2264905649 @default.
- W2116785285 cites W2269214236 @default.
- W2116785285 cites W2271992267 @default.
- W2116785285 cites W2272149927 @default.
- W2116785285 cites W2274104882 @default.
- W2116785285 cites W2281709235 @default.
- W2116785285 cites W2283857685 @default.
- W2116785285 cites W2284253990 @default.
- W2116785285 cites W2288682663 @default.
- W2116785285 cites W2313105047 @default.
- W2116785285 cites W2314699739 @default.
- W2116785285 cites W2317642686 @default.
- W2116785285 cites W2327432287 @default.
- W2116785285 cites W2331516888 @default.
- W2116785285 cites W2337277825 @default.
- W2116785285 cites W2341215846 @default.
- W2116785285 cites W2342506193 @default.
- W2116785285 cites W2342728849 @default.
- W2116785285 cites W2358616132 @default.
- W2116785285 cites W2394816133 @default.
- W2116785285 cites W2401424804 @default.
- W2116785285 cites W2415603966 @default.
- W2116785285 cites W24291559 @default.
- W2116785285 cites W2437312869 @default.
- W2116785285 cites W2466059562 @default.